Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Eur Urol. 2018 Sep 19;74(6):796–804. doi: 10.1016/j.eururo.2018.08.038

Table 2 –

Net benefit and test tradeoff results for the baseline and extended models to predict high-grade prostate cancer at a risk threshold of 10%

Statistic Result
Default strategies
NB if all men subject to biopsy (NBTrA) −0.0149
NB if no one subject to biopsy (NBTrN) 0
Baseline model
NB if baseline model is used to select patients for biopsy 0.0393
Detected HG-PCa without unnecessary biopsies 3.9 per 100 patients
Test tradeoff, patients biopsied per detected HG-PCa 25.4
Extended versus baseline model
NB if extended model is used to select patients for biopsy 0.0507
NB difference between extended and baseline models 0.0114
Additional HG-PCa detected (without change in unnecessary biopsies) when using the extended model rather than the baseline model 1.14 per 100 patients
Test tradeoff, patients undergoing TRUS per additionally detected HG-PCa 87.7
Test tradeoff, patients undergoing TRUS per avoided unnecessary biopsy 9.7

HG-PCa = high-grade prostate cancer; NB = net benefit; TrA = treat all; TrN = treat none; TRUS = transrectal ultrasound.